The webinar hosted by the NEL Training Hub and Teratogenic Medicines Safety Improvement Group (TMSIG) will provide an update on risks associated with valproate use in girls and women of childbearing potential and boys and men of reproductive potential.
It will cover the latest resources to support with implementing the new valproate safety measures and regulations locally, launch the NEL Valproate dashboard and templates to support with monitoring patients at risk.
By the end of the webinar, participants will be able to:
- Describe the current risks and measures to mitigate risks associated with valproate use in girls and women of childbearing potential and boys and men of reproductive potential.
- Understand the updated safety measures when reviewing patients prescribed valproate including risk acknowledgment, PREVENT (pregnancy prevention programme), referral pathways and tools to support communication with patients.
- Use resources shared to assess working practices locally to support safer valproate prescribing.
Speakers
- Natasha Callender – Head of Medicines Optimisation – Safety Quality & Governance | NEL ICB
- Dr Roberto Tamsanguan – Clinical Director for Tower Hamlets, Tower Hamlets Together & NHS North East London and NHS NEL Teratogenic Medicines Safety Improvement Group (TMSIG) Chair
- Geoff Ingram – Project Manager, NHS North East London
- Ash Gautam – Business Analyst, NHS North East London
- Sunitha Tanikella – Developer, NHS North East London
Audience
- Clinical Pharmacists in General Practice, Community Pharmacists, General Practitioners, PCN Pharmacists, Pharmacy technicians.
